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Abstract Recently an association between the use of calcito-
nin and cancer has been postulated. We reviewed the biolog-
ical rationale and performed an additional analysis of histori-
cal data with respect to the possibility. An association cannot
be excluded, but the relationship is weak and causality is un-
likely. The purpose of the present study is to review the
strength of association and likelihood of a causal relationship
between use of calcitonin and cancer. We reviewed the evi-
dence for this association, including the molecular signaling
mechanisms of calcitonin, preclinical data, an Bexperiment of
nature,^ and the results of a previous meta-analysis which
showed a weak association. We performed an additional
meta-analysis to incorporate the data from a novel investiga-
tional oral formulation of salmon calcitonin. Review of the
literature did not identify a cellular signaling mechanism of
action which might account for a causal relationship or toxi-
cologic or postmarketing data to support the thesis. Additional
clinical results incorporated into previous meta-analyses
weakened but did not completely negate the possibility of
association. A causal association between calcitonin use and
malignancy is unlikely, as there is little biological plausibility.
The preponderance of nonclinical and clinical evidence also
does not favor a causal relationship.
Keywords Cancer . Meta-analysis . Review . Salmon
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Introduction
Calcitonin is a 32-amino acid peptide hormone present in
mammals, fish, birds, and reptiles. In humans, calcitonin
(hCT) is produced by the parafollicular (C) cells of the thyroid
gland in response to increases in extracellular levels of calci-
um. The exact role of calcitonin in human health and disease
continues to be elucidated, but it has long been thought to play
an important role in bone and mineral homeostasis, particular-
ly with respect to its ability to regulate calcium metabolism.
However, some questions remain about the exact physiologic
role of calcitonin. For example, no calcitonin deficiency state
has ever been described. This has led some to hypothesize that
calcitonin is a vestigial hormone [1]. However, recently, more
complex signaling pathways of calcitonin in bone physiology
have been described, and as is the case with parathyroid hor-
mone (PTH), the pharmacologic activity may differ from the
physiologic role [2].
Calcitonin has long been known to have an anti-resorptive
effect on bone, mediated via calcitonin receptors (CTr) present
on osteoclasts. CTr are also present in other tissues, most
notably kidney and brain; in situ hybridization studies suggest
a broader spectrum of tissues containing CTr, including pros-
tate, as well as the exocrine glands in the pancreas, and stom-
ach [3]. Salmon calcitonin (sCT) has approximately 50 %
amino acid homology to hCT but has anti-resorptive proper-
ties in human bone approximately 40 times as potent as those
of hCT and a longer half-life [4]. It is these properties of sCT
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that have allowed its use for decades as a therapeutic agent for
postmenopausal osteoporosis, Paget’s disease, and other dis-
eases of bone. sCT was first licensed for use in the USA in
1975. The most commonly used form of sCT, nasal spray, has
been used in the USA for approximately 20 years and is cur-
rently indicated for the treatment of osteoporosis in women
greater than 5 years postmenopause when alternative treat-
ments are not suitable [5].
In its decades of use, few safety concerns have been raised
for calcitonin. However, in 2012, the European Medicines
Agency (EMA) suspended calcitonin nasal spray from the
market and limited the duration of use of other calcitonin
products due to a putative association with cancer [6]. This
was triggered by the observation of a greater number of pros-
tate cancer cases at the time of an interim analysis of an oral
investigational sCT product being studied in osteoarthritis.
The product in question, SMC021, was being evaluated in
two large phase 3 trials of osteoarthritis (OA). Upon conclu-
sion of the trials, no imbalance in prostate cancer was ob-
served, and the issue was not discussed in the final publication
of these trials [7, 8]. However, the interim findings prompted a
retrospective review of prior randomized trials, which led to
the EMA’s action. In March 2013, the US Food and Drug
Administration (FDA) convened a joint meeting of the
Advisory Committee for Reproductive Health Drugs and the
Drug Safety and Risk Management Advisory Committee to
address this issue in the US. Subsequent to this meeting, in
March 2014, the US prescribing information for all sCT prod-
ucts (nasal spray and injectable) was revised to note that the
results of a meta-analysis Bsuggest(s) an increased risk of ma-
lignancies in calcitonin-salmon-treated patients compared to
placebo^ [5]. However, no Bblack box^ warning was incorpo-
rated. Also, the indication was revised such that it is now
indicated for treatment of postmenopausal osteoporosis in
women greater than 5 years postmenopause Bwhen alternative
treatments are not suitable.^ The statement that Bfracture re-
duction efficacy has not been demonstrated^ was also added.
In this paper, we review the biological plausibility of the
putative association of calcitonin and oncogenicity with re-
spect to cellular signaling mechanisms, the preclinical carci-
nogenicity data, and results of an additional meta-analysis
which incorporates the results of another investigational oral
formulation of sCT. We also discuss the implications of an
experiment of nature, medullary thyroid cancer.
Signaling mechanisms
As noted above, calcitonin elicits its biologic effect by binding
to CTr, which is a member of a subfamily of the seven trans-
membrane domain G-protein-coupled receptor superfamily
that includes glucagon-like peptide 1, glucagon, pituitary ade-
nylate cyclase (AC)-activating polypeptide, corticotropin-
releasing factor, gastric inhibitory polypeptide receptors, and
PTH/PTH-related peptide [9]. It has long been known that
some malignant cells express CTr [10]. Binding to CTr acti-
vates AC which results in an increase of intracellular cyclic
adenosine monophosphate (cAMP). Increases in cAMP di-
rectly activate two classes of effector proteins: protein kinase
A (PKA) and the guanine nucleotide exchange factor EPAC.
With respect to cancer-relevant phenomena, cAMP/PKA is
known to regulate cell proliferation, apoptosis, and motility;
in most cells, cAMP serves to inhibit cell growth [11]. The
growth-suppressive activities of cAMP/PKA are mediated by
a number of signaling pathways, and this effect of cAMP,
mediated via sCT, has been shown, e.g., in a line of malignant
breast cancer cells [12]. The best understood link between
PKA and suppression of proliferation occurs by repressing
ERK. In addition, it should be noted that one of the best
studied prostate cancer cell lines, DU-145, has been reported
to show decreased ERK activity and decreased c-Jun expres-
sion in response to calcitonin [13]. Since ERK activity is
closely correlated to cell cycle progression, it is doubtful that
calcitonin would promote proliferative behavior in this partic-
ular prostate cancer cell line.
The Shah group has reported that (a) exogenously added
hCT induces DNA synthesis in prostate cancer LNCaP and
PC-3M cells [14], (b) hCT, acting through Gs/cAMP and
Ca2+ pathways, induces production of a CD44 splice variant
that is associated with increased invasiveness [15–17], (c)
calcitonin stimulates angiogenesis [18], and (d) calcitonin
can promote in vivo metastases of PC3 prostate cancer cells
[19]. These data point to an oncogenic effect for calcitonin, via
activation of AC and increases in cAMP, in these prostate
cancer cell lines. These results, however, conflict with other
published studies of the biology of calcitonin. For example,
Macchia et al. reported that elevated cAMP inhibits the
growth of LNCaP cells and the Ritchie group demonstrated
that hCT decreased proliferation of both PC-3 and DU-145
cells, consistent with the role of elevated cAMP suppressing
cell growth [20, 21]. These results are further supported by
Segawa, who reported that DU-145 cells treated with calcito-
nin resulted in decreased ERK activity and decreased c-Jun
[22]. Since ERK activity is closely correlated with suppres-
sion of cell proliferation, these results support the findings of
Ritchie with respect to the results for PC-3 and DU-145 cell
lines. Nakamura reported that gastrin-releasing peptide and
calcitonin gene-related peptide (CGRP) increased tumor cell
invasion of DU-145 cells whereas calcitonin did not [23].
GRP and CGRP also increased the tumor invasiveness of
PC-3 cells while calcitonin did not. The effect of CGRP is
of interest since the exposure required for calcitonin to achieve
a positive effect on LNCaP cells was 10 ng/ml, approximately
1000 times greater than the Cmax achieved with nasal sCT
[21]. These highly elevated levels of calcitonin have the po-
tential to cross react with CGRP receptors and might explain
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the some of the contradictory findings of Shah et al., calling
into question his postulate linking calcitonin to prostate
cancer.
More recently, Tsagaraki et al. conducted an experiment in
which MG63 osteosarcoma cells exposed to calcitonin dem-
onstrated an NF-κB-dependent induction of fibronectin, an
e x t r a c e l l u l a r m a t r i x c ompon e n t , a n d ma t r i x
metalloproteinase-9 (MMP-9), a combination that is often as-
sociated with oncogenic processes [24]. However, in response
to calcitonin, these same cells were also found to express
elevated levels of tissue inhibitor of metalloprotease (TIMP)-
1 and TIMP-2, which oppose the action ofMMP-9 andMMP-
2, respectively. Given these complexities, and the fact that
these studies were carried out in vitro in a single cell line, their
clinical relevance is not clear.
In summary, there are no data which demonstrate that cal-
citonin can induce carcinogenic transformation. The data with
respect to calcitonin’s ability to promote tumor aggressiveness
are inconsistent and contradictory.
Preclinical studies
Agents for use as human pharmaceuticals are required to un-
dergo rigorous in vitro and in vivo testing for general toxicity,
genotoxicity, and carcinogenicity prior to licensure. The latter
is typically performed in multiple species. In such studies,
sCT was not mutagenic in multiple bacterial strains, nor was
it clastogenic in chromosome aberration tests of Chinese ham-
ster ovary V79 cells [5]. Neither 1-year chronic toxicity stud-
ies in Sprague-Dawley rats nor formal carcinogenicity studies
of sCT in Sprague-Dawley rats and CD-1mice dosed for up to
2 years at doses 39 to 390 times the maximum recommended
subcutaneous nor intranasal doses yielded evidence of carci-
nogenicity. The sole issue arising in nonclinical testing was
the finding of decreased latency period in nonmalignant pitu-
itary adenomas in rodents, which occur with a background
frequency of 34–94 % [7]. However, there was no evidence
of malignant transformation of these tumors, nor is it believed
to be relevant to human use. The prescribing information for
current calcitonin products states BIn female Sprague Dawley
rats, the incidence of pituitary adenomas after two years was
high in all treatment groups (between 80 % and 92 % includ-
ing the control groups) such that a treatment-related effect
could not be distinguished from natural background
incidence^ [5].
Consistent with these data, Sondergaard et al. created
transgenic mice over-expressing sCT. These mice were
not noted to have an increased risk of cancer, although
the publication did not state that toxicologic examination
was performed [25].
In summary, in vivo animal data did not identify a risk of
malignancy following exposure to sCT.
Calcitonin-producing tumor
If calcitonin does not itself cause cancer, a possible alternative
hypothesis to support a putative relationship between calcito-
nin and increased cancer risk is to suggest that calcitonin
elicits a nonspecific tumor-promoting effect. An experiment
of nature is medullary thyroid cancer (MTC), an unusual but
not rare tumor of the parafollicular (C) cells of the thyroid. It
may occur sporadically or as a component of several multiple
endocrine neoplasia (MEN) constellations. Individuals with
MTC may elaborate extraordinarily high levels of hCT, and
serum hCT is used as both a diagnostic and prognostic factor
in the approach to treatment [26]. If the hypothesis that calci-
tonin is a nonspecific oncogen is correct, it could be expected
that individuals with MTC would have a high likelihood of
second primary cancers, as many tumor types are associated
with bidirectional risk of a second primary malignancy. The
US Surveillance, Epidemiology and End Results (SEER) pro-
gram collects data on all persons diagnosed with cancer in
specific geographic regions. Using nine SEER registries,
Ronckers et al. examined the likelihood of a second primary
malignancy after the occurrence of thyroid cancer(s) [27]. The
authors were able to identify 884 cases of MTC which were
followed for a median of 8 years. These individuals did not
show evidence of an increased risk of secondary malignan-
cies, as opposed to individuals with papillary and follicular
thyroid carcinoma, who did show evidence of increased risk.
These data do not support an association between hCT and
increased risk of malignancy.
Meta-analysis
In November 2010, the sponsor of an investigational oral cal-
citonin product being studied in two phase 3 trials (each 2-
year duration) of OA informed regulatory authorities of an
imbalance in prostate cancer in male study participants [6,
7]. At the time of the notification, one of the trials was ongoing
and the other complete. Following an extensive investigation,
including retrospective screening of study participants and
measurement of serum prostate-specific antigen (PSA) levels
and completion of the trials, final data did not ultimately re-
veal an increased risk of prostate cancer (5.4 % [20/365] of
male calcitonin recipients vs. 4.0 % [16/405] of placebo recip-
ients) [7]. In subjects diagnosed with prostate cancer, Gleason
scores did not differ significantly for subjects who had re-
ceived sCT compared to placebo subjects (6.9 vs. 6.4, p=
0.27). Most of these individuals were found to have had high
PSA levels at baseline which would have been discovered on
routine screening. PSA levels were not accelerated in sCT
recipients compared to placebo.
Following the initial signal of a potential increase in pros-
tate cancer incidence, a literature search was conducted, and
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the sponsor, Novartis Pharmaceuticals, conducted a meta-
analysis of 17 historical studies of nasal spray calcitonin [6,
28]. The methods and results from this analysis have been
extensively reported in publically available regulatory docu-
ments [6, 7, 29]. All but two of these trials were limited to
women. They included daily doses ranging from 100 to
400 IU per day (the licensed dose of Miacalcin® nasal spray
is 200 IU/day). The results of this analysis suggested a small
increased risk of developing any cancer in calcitonin recipients
compared to placebo (odds ratio [OR] 1.61 [95 % confidence
interval (CI), 1.11–2.34]). The authors then excluded four tri-
als in which no cases of cancer occurred Baccording to the Peto
method^ [28]. In this analysis, the ORwas 1.9 (CI 1.27–2.84).
The most frequently reported cancer was basal cell carcinoma,
but many different types of cancer were reported in calcitonin
and placebo recipients. Analysis by dose of calcitonin did not
suggest any dose response, and the duration of exposure was
similar in calcitonin-treated cases to placebo-treated cases
(CI 21.8 vs. 22.4 months). The increased risk observed in this
analysis was almost entirely attributable to one large study,
known as the PROOF trial [29, 30].
In 2013, the US FDA performed its own meta-analysis,
incorporating data from Novartis’ investigational oral calcito-
nin into the above-described nasal spray analysis (and one
additional historical nasal spray study) [7]. These data were
subsequently included in the prescribing information for all
calcitonin products in the USA [5]. In this analysis, which was
expressed in terms of risk difference (RD) rather than OR, the
RD for the development of any cancer in sCT-treated patients
exceeded that of placebo-treated patients by 1 % (95 % CI,
0.3, 1.6). When basal cell cancer was excluded, the risk was
not significant as the RD was 0.5 % (95 % CI, −0.1, 1.2),
despite which the prescribing information states that
Bimbalances in risk were still observed^ [5].
An alternative formulation of recombinant sCT for oral
administration is in late clinical development for postmeno-
pausal osteoporosis [31]. Based upon publically available data
and data from Tarsa Therapeutics’ phase 2 and 3 studies of its
investigational oral sCT, one of the authors (GW) performed
an additional meta-analysis to further explore a possible asso-
ciation between sCT and cancer. The analysis included data
from 22 randomized, controlled clinical trials with calcitonin-
salmon (nasal spray or oral investigational oral formulations).
Essentially, this analysis incorporated available data from the
original 17 trial meta-analyses of Heep [28] (including the
studies with zero events), the three large oral phase 3 trials
of an investigational oral of calcitonin formulation studies
sponsored by Novartis (including the two phase 3 osteoarthri-
tis studies and a third study in postmenopausal women with
osteoporosis), and the two trials of a different oral formulation
of sCT sponsored by Tarsa Therapeutics, Inc (Fig. 1, study
201 and study 801). These two trials, each approximately
1 year in duration, have been described elsewhere; neither trial
showed an increased incidence of cancer in calcitonin recipi-
ents, nor was there an excess risk when data from the two trials
were pooled [31–33]. The analysis employed methods that
were intended to replicate the data in Table 9 of the FDA’s
background document for the joint advisory committee meet-
ing [7]. Therefore, this analysis considered RD estimates for
each trial and a meta-analysis using a Mantel-Haenszel-type
method to estimate the pooled RD for all strata, assuming a
fixed effects model.
First, the data displayed in Table 9 of the FDA’s briefing
book were reproduced utilizing RevMan software version 5.2
(http://tech.cochrane.org/RevMan). This software employs
the same fixed effect method and uses a forest plot to
display the frequency data and RD estimates with 95 % CIs
(provided both in numeric and graphic formats). In addition,
the weight of the contribution of each study to the overall,
meta-analytic RD result is provided. The standard tests for
association as well as the Cochran Q-test and I2 measure for
heterogeneity were calculated. The data derived by the US
FDA were replicated exactly, except for slight differences in
the 95 % CI values for zero-event studies: the overall RD was
identical (please note that there is an apparent addition error in
the denominator for the placebo group in Table 9 of the FDA’s
background document, which should total 4706 and not
4687). Secondly, the adverse events consistent with cancer
were incorporated from the two Tarsa-sponsored studies.
The resultant meta-analysis and forest plot are displayed in
Fig. 1. A total of 11,489 unique individuals, including males,
were included in this analysis. The trials ranged in duration
from 6 months to 5 years; the two Tarsa-sponsored studies
were 48 weeks and 1 year in duration [31, 32].
The forest plot displays the frequency data and RD esti-
mates with 95 % CIs (provided in both numeric and graphic
formats) for each of the studies. The Cochrane Q-test (p=
0.44) and the I2 measure indicate that heterogeneity is not an
issue. As a result, weights based on the fixed effects model
were used to combine the study estimates, yielding the meta-
analytic RD of 0.90 % (95 % CI, 0.21 to 1.58 %) and the test
of association indicates that this RD is significant (p=0.01).
As noted previously, the data are heavily influenced by a sin-
gle large 5-year trial (CT320 [PROOF]), resulting in a slight
increased risk of any malignancy [30].
Postmarketing data
Data derived from spontaneous reports of adverse events to
regulatory authorities have well-known limitations including
absence of proof of causality, the presence of co-morbidities,
and other limitations such as knowledge of duration of use and
total exposure. Nonetheless, sCT has been available and widely
used for many decades, such that even a faint signal might be
apparent. In anticipation of the 2013 advisory committee, the
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USFDAperformed a review of spontaneously reported adverse
events of malignancy in calcitonin recipients and a data mining
exercise to look at a possible association [7]. Usage data includ-
ed reports from the US Adverse Event Reporting System
(AERS) and multiple proprietary drug utilization databases.
The agency concluded that its findings Bdid not identify any
potential signal for prostate cancer or other malignancies in the
postmarketing data,^ nor in the data mining exercise [7].
Discussion
Calcitonin has been in use for decades, and many millions of
individuals have been exposed to pharmaceutical doses of
sCT; it remains in use in many countries throughout the world,
including the USA. An association with cancer, particularly a
causal relationship, would clearly be important information.
Our meta-analysis is consistent with a small increased risk
of cancer in calcitonin recipients when combining all types of
malignancies; however, the data are not strongly persuasive of
such an association in our opinion; the evidence of a causal
relationship is even weaker. This interpretation is consistent
with others who have also found the evidence to be of poor
quality [34]. A large nested case-control study of the use of
calcitonin nasal spray in women with postmenopausal osteo-
porosis found that there was no association with Ball cancer^
but that there was a positive association (increased risk) for
liver cancer and a negative association (decreased risk) for
breast cancer in calcitonin users [35]. In our opinion, these
results are likely due to chance given the many types of cancer
for which a possible association was sought. The authors con-
cluded that that the results Bdid not completely support^ the
decision to discontinue use of calcitonin.
For many years, the criteria proposed by Bradford Hill in
1965 have been used to differentiate a cause and effect rela-
tionship from a noncausal association with respect to epide-
miologic and environmental factors and disease [36]. The
same criteria have been useful in the pharmacovigilance arena
[37]. These criteria include strength, consistency, specificity,
temporality, biological gradient, plausibility, coherence, and
analogy.
With respect to the strength of association, the signal is
weak and not statistically significant for any individual study.
The lower bound of the 95 % CI of the RD is close to 0, and
specificity and biological plausibility are absent.
The data are inconsistent on a number of levels, including
results of formal preclinical toxicology data, in which calcito-
nin administration resulted in a lack of tumors in tissues of
rodent species/strains which have a background incidence of
spontaneous tumors. Therefore, the postulate of nonspecific
tumor promotion is inconsistent with basic experimental car-
cinogenicity findings. Furthermore, no signal was noted in the
largest study (Fig. 1, A2303) with the greatest patient-years of
exposure. No temporality was observed; i.e., time to onset was
not different in the intranasal group compared to placebo re-
cipients. No signal is apparent in postmarketing surveillance
data despite many years of use.
Specificity is entirely absent; the original NVS meta-
analysis of 17 intranasal trials included 19 different types of
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Fig. 1 Meta-analysis of all
available nasal and oral trials
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promoters is inconsistent with the fundamental principle that
tumor promoters are organ specific, based on several decades
of experimental carcinogenesis studies elucidating the mech-
anism of tumor formation.
A biological gradient is not apparent, as no dose-response
was evident in the FDA’s analysis [7]. In PROOF, there was an
inverse relationship between total exposure and development
of the two most commonly reported malignancies, BCC and
breast cancer.
There are no experimental data that show a cause and effect
relationship, aside from prostate cancer data from the Shah
lab. Ironically, prostate cancer is the only cancer for which a
systematic evaluation was performed in the clinic, in two
large OA trials. For this tumor type, the thesis of increased
risk was ultimately refuted.
We are not aware of an analogy, e.g., in which a drug
substance serves as a nonspecific oncogen or tumor promoter
and whose effects are not observed in formal carcinogenicity
studies.
None of these factors alone can disprove a causal relation-
ship, but together, they provide a compelling argument against
causality. Based on the preclinical literature, the known mech-
anism of action of calcitonin, and the receptor distribution,
there is no real biological plausibility for a Bpan cancer^ caus-
al association, nor for any single cancer type.
Our analysis, like those preceding it, has important limita-
tions. None of the 22 trials included in the meta-analysis was
designed specifically to identify an increased risk of malig-
nancy, nor were cancer cases adjudicated in blinded fashion.
In all cases, the analyses refer to adverse events reported as
malignancy or consistent with a malignant adverse event.
Furthermore, the enrolment criteria and duration of use varied
in these trials. The exposure to sCT afforded by the various
routes of administration and investigational oral formulations
may not be comparable.
Conclusion
There is a need for additional agents for the treatment of os-
teoporosis, and all currently available agents have limitations.
Calcitonin has been shown to have a modest but consistent
salutary effect on lumbar spine bone mineral density, and at a
dose of 200 IU/day, intranasal calcitonin was shown to have a
positive effect on the risk of vertebral fracture [30, 31]. At
present, the therapeutic milieu for the treatment of postmeno-
pausal osteoporosis is not optimal, as the use of available
agents has contracted, likely due to fears on the part of patients
and providers regarding the complications of anti-resorptive
agents, and recommendations for Bdrug holidays^ [38, 39]. To
our knowledge, calcitonin has never been associated with
atypical femoral fracture or osteonecrosis of the jaw.
Calcitonin may have a role in patients for whom other agents
are unsuitable or otherwise contraindicated, consistent with its
current US prescribing information. An oral formulation, cur-
rently in development, may be desirable for some patients.
Current understanding of the biology and mechanism of
action of sCT does not support a role as an oncogen or
tumor-accelerating agent. Such evidence is lacking in preclin-
ical carcinogenicity, genotoxicity, and mutagenicity studies
and, in general, biological plausibility. Consideration of all
of the available data suggests that the association between
calcitonin and cancer is weak, antithetical to the known biol-
ogy of calcitonin, and not causal.
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